Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

23 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Expression and metylation data from A2780 (cisplatin-sensitive) and Round5 A2780 (cisplatin-resistant) cell lines

ABSTRACT: This SuperSeries is composed of the following subset Series: GSE15372: Expression data from A2780 (cisplatin-sensitive) and Round5 A2780 (cisplatin-resistant) cell lines. GSE15373: Promoter CpG island methylation data from A2780 (cisplatin-sensitive) and Round5 A2780 (cisplatin-resistant) cell lines. Refer to individual Series

ORGANISM(S): Homo sapiens

SUBMITTER: Meng Li

PROVIDER: E-GEOD-15709 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Publications

Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer.

Li Meng M Balch Curt C Montgomery John S JS Jeong Mikyoung M Chung Jae Hoon JH Yan Pearlly P Huang Tim H M TH Kim Sun S Nephew Kenneth P KP

BMC medical genomics 20090608

<h4>Background</h4>Cisplatin and carboplatin are the primary first-line therapies for the treatment of ovarian cancer. However, resistance to these platinum-based drugs occurs in the large majority of initially responsive tumors, resulting in fully chemoresistant, fatal disease. Although the precise mechanism(s) underlying the development of platinum resistance in late-stage ovarian cancer patients currently remains unknown, CpG-island (CGI) methylation, a phenomenon strongly associated with abe ...[more]

PMID: 19505326

Similar Datasets

Promoter CpG island methylation data from A2780 (cisplatin-sensitive) and Round5 A2780 (cisplatin-resistant) cell lines.

Project description:Cisplatin and carboplatin are the primary first-line therapies for the treatment of ovarian cancer. However, resistance to these platinum-based drugs occurs in the large majority of initially responsive tumors, subsequently resulting in a poor long-term prognosis. To model the onset of drug resistance, and investigate the DNA methylation alterations associated with cisplatin resistance, we treated clonally derived, drug-sensitive A2780 epithelial ovarian cancer cells with increasing concentrations of cisplatin. After several cycles of drug selection, the isogenic drug-sensitive and -resistant pairs were subjected to global CGI methylation microarray analyses. We treated clonally derived, drug-sensitive A2780 epithelial ovarian cancer cells with increasing concentrations of cisplatin. After several cycles of drug selection, the isogenic drug-sensitive and -resistant pairs were subjected to global CGI methylation analyses by differential methylation hybridization (DMH) using a customed 44K promoter CGI microarray.

2010-06-19 | E-GEOD-15373 | biostudies-arrayexpress

Expression data from A2780 (cisplatin-sensitive) and Round5 A2780 (cisplatin-resistant) cell lines.

2009-04-17 | E-GEOD-15372 | biostudies-arrayexpress

Differences in gene expression in A2780C20 vs. A2780

Project description:Differences in gene expression in A2780C20 vs. A2780 and A2780 treated with temsirolimus at 24-hr and 48-hr. The A2780 are human ovarian carcinoma cellls were purchased to the European Collection of Cell Cultures (ECACC). The A2780CP20 are cisplatin resisatnt cells derived of the A2780 cells. A2780CP20 cells were generated by Dr. Robert Ozols (J. Natl. Cancer Inst. 84, 264-267 (1992) by treatment of A2780 cells with incresing concentrations of cisplatin. The goal of this study is to determine whether the cisplatin and temsirolimus resistance are co-regulated. The objectives of this study are to identify additional genes differentially expressed in cisplatin sensitive and cisplatin resistant ovarain cancer cells and the changes in gene expreession upon temsirolimus treatment of A2780 cells. RNA was isolated from A2780, A2780CP20, A2780 plus temsirolimus 24-hr, and A2780 plus temsirolimus 48-hr. Labelled samples were hybridized to Affymetrix GeneChip Gene 1.0 ST Human Arrays.

2013-10-25 | E-GEOD-51683 | biostudies-arrayexpress

Transcription profiling by array of human A2780 ovarianc cancer cells and cisplatin resistant derivate cells treated with cisplatin or liposomal cisplatin

Project description:A2780 ovarian cancer cells and a cisplatin resistant derivate of A2780 cells, obtained from ECACC, UK, No. 93112519 [A2780] and No. 93112517 [A2780 cis] were seeded out in T-75 flasks at a density of 2x106 for A2780sens and 3x106 for A2780cis cells in 15 ml of medium and preincubated overnight. Medium was removed and 15 ml fresh medium (37M-0C) with different concentrations of cisplatin, liposomal cisplatin or empty liposomes were added and incubated for 72 h at 37M-0C in a 5% CO2 incubator. In case of A2780sens cells, 1.72 M-5M cisplatin (IC50 concentration) and in case of A2780cis cells 8.94 M-5M cisplatin (IC50 concentration) were added. Liposomal formulations contained equal cisplatin concentrations. Empty liposomes were added in the same concentration as the liposomal cisplatin, to analyze the impact of liposomal lipids (A2780sens: 0.80M-5mol lipid, A2780cis: 4.15 M-5mol lipid). After incubation, medium was removed and cells were washed thrice with 10 ml PBS. 1 ml RLT-buffer was added and cells lysates were stored at -80M-0C until RNA extraction.

2010-12-13 | E-MEXP-2840 | biostudies-arrayexpress

Flavopiridol profiling on A2780

Project description:The effects of the CDK inhibitor Flavopiridol on the A2780 human adenocarcinoma ovary cell line were analysed by gene expression profiling. A2780 cells were treated with Flavopiridol for 6 hours at a dose equal to 5 times the IC50. Untreated A2780 cells were used as a control. Two replicates per treatment.

2010-07-14 | E-GEOD-18504 | biostudies-arrayexpress

CDK inhibitor PHA-793887 profiling on A2780

Project description:The effects of the CDK inhibitor PHA-793887 on the A2780 human adenocarcinoma ovary cell line were analysed by gene expression profiling. The A2780 cell line was treated with PHA-793887 (CDK-887) for 6 hours at a dose equal to 5 time the IC50. Untreated A2780 cells were used as a control. Two replicates per treatment.

2010-07-14 | E-GEOD-18498 | biostudies-arrayexpress

CDK inhibitors PHA-848125 and PHA-690509 profiling on A2780

Project description:The effects of the CDK inhibitors PHA-848125 and PHA-690509 on the A2780 cell line were analysed by gene expression profiling. The A2780 cell line was treated with PHA-848125 (CDk-125) or PHA-690509 (CDk-509) for 6 hours at a dose equal to 5 times the IC50. Untreated A2780 cells were used as a control. Three replicates per treatment.

2010-07-14 | E-GEOD-18486 | biostudies-arrayexpress

CDK inhibitors and flavopiridol profiling on A2780 and MCF7 cells

Project description:This SuperSeries is composed of the following subset Series: GSE18486: CDK inhibitors PHA-848125 and PHA-690509 profiling on A2780 GSE18498: CDK inhibitor PHA-793887 profiling on A2780 GSE18501: CDK inhibitor PHA-848125 gene expression profiling on MCF7 cell line GSE18504: Flavopiridol profiling on A2780 GSE19638: Compounds profiling on MCF7 Refer to individual Series

2010-07-14 | E-GEOD-18552 | biostudies-arrayexpress

Comparing control and IL17A treated A2780-derived ovarian cancer stem cell

Project description:A2780-derived ovarian cancer stem cells were in vitro cultured in the presence of 10 ng/mL basic fibroblast growth factor , 20 ng/mL epidermal growth factor , 5 M-NM-<g/mL insulin, 0.4% bovine serum albumin. Then ovarian cancer stem cells were stimulated for 4 and 6 hours in the presence or absence of 250ng/ml IL17A. Total RNA was isolated and processed according to the AgilentmanufacturerM-bM-^@M-^Ys standard protocols Gene expression in ovarian cancer stem cells from A2780 cell line was measured at IL17A stmulated (4 and 6 hours) and un-stmulated.

2012-07-27 | E-GEOD-39698 | biostudies-arrayexpress

A2780 and OVCAR-3 Cells:Control vs. LS-98 treated

Project description:Transcriptional profiling of human ovarian cancer cells comparing control vehicle-treated A2780 and OVCAR-3 (Human ovarian cancer cell lines) cells with A2780 and OVCAR-3 cells treated with 5μM LS-98 for 24 hours.Goal was to determine the effects of LS-98 compound on the global A2780 and OVCAR-3 cells gene expression. One-condition experiment, control vehicle-treated A2780 and OVCAR-3 vs. LS098 treated-A2780 and OVCAR-3 cells. Biological replicates: 2 replicates.

2011-06-01 | E-GEOD-29668 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data